Johannsson G, et al. - An inquiry was set up with regard to the safety, local tolerability and treatment satisfaction of once-weekly somapacitan vs once-daily Norditropin in patients aged 18-79 years with adult growth hormone deficiency (AGHD). Based on the yielded data, it was determined that somapacitan was well tolerated with no safety issues. Findings also reported that once-weekly somapacitan was more convenient compared to once-daily Norditropin